Oral Anticoagulation Alone Best for Stable CAD Patients With AF: Meta-Analysis

Why It Matters

Simplifying antithrombotic therapy lowers death and bleeding risk while preserving ischemic protection, reshaping prescribing habits and reducing healthcare costs.

Key Takeaways

• OAC monotherapy cuts cardiovascular death by 31%
• Major bleeding drops 54% with OAC alone
• No increase in MACE, MI, or stroke
• Benefits persist in high‑risk thrombotic patients
• Supports guideline shift to anticoagulation‑only after 6 months

Pulse Analysis

The management of patients who have both stable coronary artery disease and atrial fibrillation has long been a balancing act between preventing clot‑related events and avoiding dangerous bleeding. Historically, clinicians added a single antiplatelet agent to oral anticoagulation, assuming that the extra platelet inhibition would further reduce myocardial infarction risk. However, real‑world practice has shown higher bleeding rates, and prior smaller studies offered mixed conclusions about the net clinical benefit.

The new meta‑analysis, aggregating data from six contemporary trials such as ADAPT AF‑DES and AFIRE, provides a clearer picture. Across nearly 6,000 participants, OAC alone delivered a 31% relative reduction in cardiovascular death and a striking 54% drop in major bleeding, while rates of MACE, MI, stroke, and stent thrombosis remained statistically unchanged. These findings held true even for patients classified as high‑risk for thrombotic events, suggesting that the added antiplatelet does not confer additional ischemic protection once the acute post‑PCI window has passed.

For the cardiovascular community, the implications are immediate. Guideline committees are likely to endorse OAC‑only strategies after six months of stable disease, streamlining therapy, cutting costs, and improving patient safety. Remaining questions include the optimal timing for dropping the antiplatelet and whether specific direct oral anticoagulants perform differently in this context. Ongoing trials like MATRIX‑2 will refine these recommendations, but the current evidence already makes a compelling case for simplifying long‑term antithrombotic regimens.